The history of Sildenafil presents a complex case for observers in the medicinal sector. While initially a blockbuster success, generating vast sums, the patent lapse and the subsequent arrival of off-brand alternatives have significantly changed income. This poses questions about the long-term viability of analogous drug innovations and suggests t